Treatment With Oral Etoposide for Childhood Recurrent Ependymomas
- 1 September 2005
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of Pediatric Hematology/Oncology
- Vol. 27 (9), 486-490
- https://doi.org/10.1097/01.mph.0000181430.71176.b7
Abstract
In this study the authors retrospectively evaluated the feasibility and effectiveness of prolonged oral etoposide therapy in children with recurrent ependymoma. Twelve ependymoma patients with documented recurrent or persistent disease were treated between May 1998 and October 2003. All patients were treated monthly with oral VP-16 administered at a dose of 50 mg/m2/d for 21 days, with a 7-day interval between cycles, for a planned minimum number of six cycles. Response (complete plus partial) after two cycles occurred in 5 of the 12 patients (41.6%). Response plus stable disease occurred in 10 of the 12 (83.3%), with a median duration of response or stable disease of 7 months (range 4-30). The median survival was 7 months; the 2-year progression-free survival was 16.7%. These results emphasize that oral etoposide is an attractive option for childhood recurrent ependymomas in terms of administration, tolerability, and neuroradiologic response.Keywords
This publication has 27 references indexed in Scilit:
- Multivariate Analysis of Clinical Prognostic Factors in Children with Intracranial EpendymomasJournal of Neuro-Oncology, 2004
- EpendymomaChild's Nervous System, 2003
- High-dose chemotherapy in childhood brain tumoursChild's Nervous System, 1999
- Intracranial ependymomas in children: A critical review of prognostic factors and a plea for cooperationMedical and Pediatric Oncology, 1998
- Phase II study of 21 day schedule oral etoposide in childrenEuropean Journal Of Cancer, 1997
- Chronic oral VP-16 for recurrent medulloblastomaPediatric Neurology, 1997
- Phase II study of daily oral etoposide in children with recurrent brain tumors and other solid tumorsMedical and Pediatric Oncology, 1997
- Recurrent Supratentorial Malignant Gliomas in ChildrenArchives of Neurology, 1997
- Response of recurrent medulloblastoma to low-dose oral etoposide.Journal of Clinical Oncology, 1996
- Recurrent brainstem gliomas treated with oral VP-16Journal of Neuro-Oncology, 1993